Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.
In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...
Roche Bobois, the global leader in the high-end furniture market and the epitome of the French Art de Vivre, publishes its latest news every month. FEBRUARY 2025 LATEST NEWS PENINSULA PARIS ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...
Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback